Why the United States is falling behind in medical cannabis research

Society · Published 19 October 2026 Swipe more like this →

In short: While many G20 nations are actively investigating cannabinoids for cancer and neurological cures, US scientists face a unique regulatory bottleneck. It is not just a lack of interest, but a complex federal monopoly that makes even small-scale studies incredibly difficult to conduct.

In the United States, the primary obstacle to cannabis research is a structural monopoly held by the National Institute of Drug Abuse (NIDA). While a scientist studying a substance like LSD only needs FDA approval to begin laboratory testing, cannabis researchers face an extra layer of bureaucracy. Once the FDA approves a study, researchers must still obtain permission from NIDA to use the specific cannabis grown by the agency. This regulatory hurdle applies even when researchers are investigating specific conditions like PTSD. The complexity is further compounded by the sheer variety of products, including edibles, vapes, and topicals, which would theoretically require separate randomized trials for each administration method.

This secondary gatekeeping is particularly challenging because NIDA's core mission is to investigate the harms of drugs, which can create a conflict of interest regarding the distribution of the plant for research. Because medical research is both expensive and time-consuming, many scientists find these cumulative barriers too high to overcome. Consequently, many researchers have simply pivoted their focus to other substances, leaving a gap in domestic data. The lack of rigorous funding means that while there is strong evidence for using CBD to treat seizures, other therapeutic claims remain much more uncertain. This uncertainty is exacerbated by the fact that cannabis contains dozens of different minor cannabinoids and terpenes in varying concentrations.

The impact of this research deficit is global. Most major G20 countries now maintain dedicated cannabinoid departments to explore the plant's potential for symptom relief and disease treatment. This leaves the U.S. at a potential competitive disadvantage. While some progress was made about ten years ago—such as when California provided $5 million to the University of California to fund studies—the fundamental difficulty of accessing regulated material remains a significant hurdle for the scientific community. The current landscape of legality is also highly fragmented. Currently, medical cannabis is legal in 38 states plus Washington, D.C., whereas 23 states and D.C. permit recreational consumption. have permitted recreational consumption.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• The real reason medical cannabis remains illegal is not a corporate conspiracy
• The high cost of a medical necessity: How stigma creates barriers
• Is legal cannabis actually safe, or does the science suggest hidden risks?
• Cannabis is ancient medicine with only a few proven modern uses
• Why global cannabis laws are shifting from total prohibition to regulated market systems
• The Geometry of Reversibility: Why Your First Scarf Shouldn't Have a Wrong Side
• Bamber Gascoigne: The Quizmaster Who Restored a Country House and Found a Masterpiece
• Why your best poker move might be the simplest one
• The physics of a bar wager: how to balance a coin on a bill
• Why poker players burn cards to prevent a Wild West cheat
• Is the balance of power a path to global peace or a recipe for catastrophe?
• Why Shiatsu Practitioners Use Their Entire Body Weight as a Tool

More in Society · Latest · A–Z · All topics